康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

(1) PROPOSED CHANGE OF A SUPERVISOR AND (2) PROPOSED CHANGE OF AUDITORS
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 CLOSURE OF REGISTER OF MEMBERS
INSIDE INFORMATION NATIONAL MEDICAL PRODUCTS ADMINISTRATION'S APPROVAL OF CLINICAL TRIAL APPLICATION FOR RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION
INSIDE INFORMATION RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR) APPROVED FOR EMERGENCY USE IN HUNGARY
NOTICE OF BOARD MEETING
Monthly Return of Equity Issuer on Movements in Securities
INSIDE INFORMATION NMPA'S GRANT OF CONDITIONAL MARKETING AUTHORIZATION FOR RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR)
INSIDE INFORMATION UPDATES ON 2020 PRELIMINARY ANNUAL RESULTS
INSIDE INFORMATION NMPA'S ACCEPTENCE OF APPLICATION FOR CONDITIONAL MARKETING AUTHORIZATION OF RECOMBINANT NOVEL CORONAVIRUS VACCINE (ADENOVIRUS TYPE 5 VECTOR)
INSIDE INFORMATION RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) GRANTED EMERGENCY USE AUTHORIZATION IN PAKISTAN

1 36 37 38 39 40 52